ESR1 and breast carcinoma: In both in vitro and in vivo settings, Elacestrant demonstrates anti-tumor efficacy against breast cancer models characterized by ER+, HER2−profiles, which exhibit resistance to Fulvestrant and cyclin-dependent kinase 4/6 inhibitors.